Lexicon Pharmaceuticals (LXRX) Total Non-Current Liabilities (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Total Non-Current Liabilities data on file, last reported at $59.6 million in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 64.81% year-over-year to $59.6 million in Q1 2026; TTM through Mar 2026 was $59.6 million, a 64.81% decrease from a year earlier, with the FY2025 full-year figure at $70.3 million, down 51.72% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $59.6 million, down from $70.3 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for LXRX reached as high as $169.3 million in Q1 2025 and fell as low as $40.5 million in Q2 2022.
• Historically, Total Non-Current Liabilities has averaged $93.3 million across 5 years, with a median of $78.2 million in 2025.
• Across the five-year window, Total Non-Current Liabilities soared 224.31% in 2022 and slumped 64.81% in 2026, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $71.8 million in 2022, then jumped by 82.65% to $131.1 million in 2023, then increased by 11.06% to $145.5 million in 2024, then sank by 51.72% to $70.3 million in 2025, then decreased by 15.22% to $59.6 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $59.6 million in Q1 2026, $70.3 million in Q4 2025, and $78.2 million in Q3 2025.